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Gout is a common inflammatory arthritis resulting 
from the crystallisation of uric acid within joints. 
It is often, but not always, associated with 
hyperuricaemia. It is common, affecting around 
2% of men aged over 30 years and women aged 
over 50 years, and its prevalence appears to 
be increasing.1 In Australian general practice, it is 
in the top 20 of chronic diseases managed 
and is seen at a rate of six per 1000 general 
practitioner encounters.2
	
Treatment	 options	 for	 acute	 gout	 include	 nonsteroidal	
anti-inflammatory	 drugs	 (NSAIDs),	 colchicine,	 systemic	
corticosteroids	and	intra-articular	aspiration	and	injection	
of	long	acting	corticosteroid,3,4	although	the	evidence	for	
these	options	is	of	varying	strength.
	 Schlesinger	 et	 al5	 performed	 a	 systematic	 review	 to	
assess	 the	 efficacy	 and	 adverse	 effects	 of	 colchicine	
compared	 to	 placebo	 or	 compared	 to	 other	 acute	 gout	
treatments.	The	 review	 results	 are	summarised	 in	Table 
1	and	how	these	results	might	affect	practice	are	shown	
in	the	case	studies	in	Table 2.
Conclusion
While	 colchicine	 has	 demonstrated	 its	 efficacy	 as	 a	
treatment	 of	 acute	 gout	 at	 the	 standard	 dosage	 of	 1	
mg	 orally,	 followed	 by	 0.5	mg	 2	 hourly,	 the	 high	 levels	
of	 gastrointestinal	 side	 effects	 limits	 its	 use	 at	 those	
doses.	The	 only	 evidence	 to	 support	 the	 use	 of	 lower	
doses	 is	 weak	 –	 coming	 from	 case	 reports	 –	 but	
this	 remains	 an	 option	 in	 patients	 in	 whom	 other	
therapies	 are	 contraindicated.	 Further	 research	 is	
required	 to	 determine	 the	 lowest	 dose	 of	 colchicine	
that	 will	 adequately	 treat	 acute	 gout,	 and	 to	 directly	
compare	 the	 efficacy	 and	 adverse	 effect	 profiles	 of	
NSAIDs	and	colchicine.
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This series of articles facilitated by the Cochrane Musculoskeletal Group (CMSG) aims to place the 
findings of recent Cochrane musculoskeletal reviews in a context immediately relevant to general 
practitioners. This article considers the place of colchicine in the management of acute gout.
Colchicine
What is its place in the management  
of acute gout? 
Table 1. Key review results5
•	 	Only	one	randomised	controlled	trial	
(RCT)	of	the	use	of	colchicine	was	
identified,	which	studied	43	predominantly	
male	participants.	Treatment	was	with	
colchicine	1	mg	orally	followed	by	0.5	mg	
every	2	hours	until	complete	response		
or	toxicity	
•	 	All	22	participants	taking	colchicine	
developed	diarrhoea	and/or	vomiting,	
beginning	at	a	median	of	24	hours,	after	a	
mean	dose	of	6.7	mg
•	 	The	number	needed	to	treat	for	colchicine	
to	result	in	at	least	a	50%	decrease	in	pain	
was	three
•	 	There	were	no	RCTs	comparing	colchicine	
to	other	treatments	of	acute	gout
•	 	In	the	review	discussion	it	was	noted	that	
there	have	been	case	reports	suggesting	
lower	doses	(0.5	mg	three	times	per	day	
or	less)	may	reduce	the	gastrointestinal	
side	effects	of	colchicine,6	but	there	was	
no	RCT	evidence	to	support	this
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Table 2. Putting evidence into practice 
Case study 1 
Mr	Squire,	50	years	of	age,	is	generally	well,	although	somewhat	overweight	
with	a	body	mass	index	(BMI)	of	29.	He	presents	to	you	with	acute	onset	of	
excruciating	pain	in	his	right	great	toe	and	a	swollen	and	erythematous	first	
metatarsophalangeal	joint.	The	classic	presentation	makes	you	immediately	
suspicious	of	gout.	You	decide	to	check	his	serum	uric	acid,	but	in	view	of	his	
pain	levels	and	the	classic	gouty	presentation,	decide	on	pharmacological	
treatment	without	immediately	performing	other	investigations.
What	immediate	treatment	do	you	choose?
As	he	is	generally	well	and	has	no	contraindication	to	the	use	of	NSAIDs	you	
decide	to	commence	indomethacin	50	mg	orally	three	times	per	day	and	to	
review	him	in	48	hours.	You	consider	the	option	of	using	colchicine,	but	in	the	
absence	of	any	evidence	of	greater	efficacy	for	this	drug	and	in	view	of	its	side	
effect	profile,	you	decide	that	NSAIDs	are	the	best	choice	at	this	point.	
Case study 2 
Mr	Yee,	aged	78	years,	presents	with	classic	gout	affecting	the	great	toe	as	
described	in	Case	1.	Mr	Yee	takes	warfarin	3	mg/day	for	atrial	fibrillation	
and	his	INR	has	been	stable	on	this	dose	for	some	time.	He	is	hypertensive	
on	enalapril	20	mg	in	combination	with	hydrochlorothiazide	6	mg,	and	is	a	
noninsulin	dependent	diabetic	controlled	by	diet	alone.	His	renal	function	
is	normal.	Importantly,	he	is	the	prime	carer	for	his	infirm,	elderly	wife	
who	is	heavily	reliant	on	him	for	her	daily	needs,	making	rapid	relief	of	his	
excruciating	pain	very	urgent.	As	in	the	previous	case,	in	view	of	his	pain	
levels	and	the	classic	gout	presentation,	you	decide	on	pharmacological	
treatment	without	immediately	performing	other	investigations	
What	treatment	do	you	consider	in	this	case?
You	are	reluctant	to	use	NSAIDs	in	view	of	Mr	Yee’s	warfarin	treatment	and	the	
concomitant	increased	risk	of	gastrointestinal	bleeding	with	NSAID	use.	While	
oral	corticosteroids	are	a	possibility,	Mr.	Yee’s	warfarin	therapy	and	NIDDM	
mean	that	there	are	potential	problems	with	gastrointestinal	bleeding,	and	
with	worsening	glucose	tolerance.	Intra-articular	injection	of	corticosteroids	
has	an	increased	risk	of	joint	haemorrhage	in	a	patient	on	warfarin.	Colchicine	
at	the	doses	used	in	the	RCT	identified	in	the	review	produces	gastrointestinal	
side	effects	that	may	further	incapacitate	Mr	Yee	and	given	his	social	situation	
this	is	not	desirable.	However,	you	note	that	lower	doses	have	been	used,	
although	the	evidence	to	support	this	is	weak.	You	decide	to	discuss	the	
options	with	Mr	Yee	so	he	is	aware	of	his	options,	and	recommend	to	him	
colchicine	at	a	dose	of	1.0	mg	followed	by	0.5	mg	three	times	per	day.	
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